Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Zepbound produced the largest average weight loss of any approved weight management medication in its main trial. That is not marketing language. In SURMOUNT-1, the highest dose reduced body weight by an average of 20.9 percent over 72 weeks.
It contains tirzepatide, made by Eli Lilly, and it works differently from every GLP-1 drug that came before it.
What Zepbound is
Zepbound is tirzepatide, injected once weekly, approved for weight management in adults.
The same molecule is sold as Mounjaro for type 2 diabetes. Same drug, same manufacturer, different brand name and different approved use. This mirrors the Ozempic and Wegovy arrangement exactly.
Doses run 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg weekly.
The dual mechanism
Every earlier drug in this field targets one receptor. Tirzepatide targets two.
GLP-1 (glucagon-like peptide-1) is the gut hormone released after eating that signals fullness, slows stomach emptying and prompts insulin release. This is what semaglutide, liraglutide and dulaglutide act on.
GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone released after eating. It also stimulates insulin, and it appears to influence how fat tissue stores and processes energy.
Tirzepatide activates both. The working theory is that combining the two produces effects neither achieves alone, particularly on fat tissue and energy expenditure rather than appetite alone.
The science on exactly why the combination works better is not fully settled. What is settled is the outcome. Adding GIP action produced substantially more weight loss than GLP-1 action by itself.
What SURMOUNT-1 found
SURMOUNT-1, published in the New England Journal of Medicine in 2022, followed adults with obesity, or overweight with a weight-related condition, but without diabetes, over 72 weeks.
| Dose | Mean weight reduction |
|---|---|
| Tirzepatide 5 mg | 15.0 percent |
| Tirzepatide 10 mg | 19.5 percent |
| Tirzepatide 15 mg | 20.9 percent |
| Placebo | 3.1 percent |
All three doses beat placebo with high statistical confidence.
A 20.9 percent average reduction is a genuinely different order of result from what earlier weight loss drugs achieved. For someone starting at 100 kg, that is roughly 21 kg on average.
Averages hide spread, and individual results varied considerably. But even the lowest 5 mg dose outperformed what most previous medications managed at their maximum.
How you take it
Zepbound starts at 2.5 mg weekly for four weeks. That starting dose is not intended to produce weight loss. Its purpose is letting your digestive system adapt.
It then increases to 5 mg, and can step up by 2.5 mg increments at intervals of at least four weeks, up to a maximum of 15 mg.
Injection goes into the abdomen, thigh or upper arm, once weekly, any time of day, with or without food. Choose a consistent day.
Unopened pens are refrigerated. They can be kept at room temperature for a limited period before use.
Reaching the top dose takes around 20 weeks if every step is taken at the minimum interval. Rushing it is the most common cause of severe side effects.
Side effects
The profile matches the GLP-1 class, because slowed stomach emptying is central to how it works.
Nausea, diarrhoea, vomiting and constipation lead the list. Abdominal pain, indigestion, fatigue and injection site reactions are also common. Hair thinning has been reported, though this is generally a consequence of rapid weight loss rather than the drug itself.
Most gastrointestinal effects are worst in the days after a dose increase and settle at a stable dose. Eating smaller portions, cutting fatty foods and drinking water steadily all help considerably.
Serious risks include pancreatitis, which shows as severe persistent abdominal pain often radiating to the back, and gallbladder disease. Rapid weight loss of any cause raises gallstone risk.
Zepbound is not used in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and not during pregnancy.
Combined with insulin or sulfonylureas, the risk of low blood sugar rises and those doses usually need adjusting.
One further point. Tirzepatide can reduce the absorption of oral contraceptives, particularly around dose increases. Anyone relying on the pill needs to discuss backup contraception with their doctor.
Who it is for
Zepbound is intended for adults with a BMI of 30 or above, or 27 and above with a weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnea.
It is used alongside reduced calorie intake and increased physical activity, not instead of them. Every trial participant received lifestyle counselling as well as the drug.
Work out your BMI first if you are unsure where you stand, since eligibility for every medication in this category is anchored to it.
Availability in Pakistan
Zepbound is not registered in Pakistan. Whatever reaches the country arrives through import channels, requires refrigerated handling, and is priced against the dollar.
Tirzepatide has also faced global supply constraints driven by demand, which affects unofficial markets faster and harder than regulated ones.
The practical problem is duration. SURMOUNT-1 measured its results at 72 weeks. That is nearly eighteen months of uninterrupted weekly injections. Sourcing that reliably through informal import channels, at import prices, is beyond most households here.
If you want to see how the 8-week program works as a locally available comparison, METASLIM™ takes the sublingual route instead. It is a registered GLP-1 pathway supplement, not tirzepatide and not a pharmaceutical GLP-1 receptor agonist, so the results are not comparable to SURMOUNT-1 figures and nobody should suggest otherwise. What it provides is appetite support with physician review built in, without the cold chain or import dependency.
Our guide to Ozempic alternatives maps the wider field, and what a GLP-1 receptor agonist is covers the underlying pharmacology.
The summary
Zepbound is the strongest approved weight loss medication currently available, and SURMOUNT-1's 20.9 percent average at the top dose is the reason.
Its dual GIP and GLP-1 action is a genuine mechanistic advance rather than an incremental improvement.
Its side effect profile is the familiar one for this class, its dose escalation is long, and its cost and availability put it out of reach for most people in Pakistan.
See current pricing and order options if you want to compare a locally registered program.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.